Updated on: 26 February 2024

1. Financial interests

a) Received research funding: any grant, contract or gift, commissioned research, or fellowship from The Cochrane Collaboration or a related organisation (i.e. any organisation related to health care or medical research) to conduct research?
No

b) Had paid consultancies: any paid work, consulting fees (in cash or kind) from a related organisation?
Yes - Providing independent medical consultation professional services to the Reformulary Group. PT is an independent committee member for a clinical trial Data Safety Monitoring Boards for FDA approved trial, funded by UCB Biopharma GmbH & SPRL and co-ordinated by Parexel International. He is an an advisory committee member of the Canadian Reformulary Group Inc., a company that reviews the evidence for health insurance companies employer drug plans.

c) Received honoraria: one-time payments (in cash or kind) from a related organisation?
No

d) Served as a director, officer, partner, trustee, employee or held a position of management with a related organisation?
No

e) Possessed share-holdings, stock, stock options, equity with a related organisation (excludes mutual funds or similar arrangements where the individual has no control over the selection of the shares)?
No

f) Received personal gifts from a related organisation?
No

g) Had an outstanding loan with a related organisation?
No

h) Received royalty payments from a related organisation?
No

2. Do you have any other competing interests that could pose a conflict of interest that would reasonably appear to be related to the primary interest?
Yes - I am [unpaid] Chair of the Management Group of a registered non-profit independent medical research organization, OMERACT, whose goal is to improve and advance the health outcomes for patients suffering from musculoskeletal conditions. OMERACT receives arms-length funding from 11 companies (Abbvie, Astra Zenaca, Aurinia, BMS, Centrexion, GSK, Horizon Pharma Inc , Janssen, Novartis, Pfizer & Sparrow).